Business context and reporting period
This is AVROBIO, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2023—not a filing for Tectonic Therapeutic, Inc. AVROBIO was a clinical-stage gene therapy company and reported no product revenue. In July 2023, after the quarter, it announced it would halt development of its programs and explore strategic alternatives.
Financial results and liquidity
| Metric | Three months ended June 30, 2023 | Six months ended June 30, 2023 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $11.1 million | $28.5 million |
| General and administrative expense | $4.6 million | $12.5 million |
| Net income (loss) | $67.5 million | $42.5 million |
| Operating cash flow | Not separately presented | $(34.9) million |
Quarterly and six-month net income included an $83.7 million gain on the cystinosis-program asset sale, net of transaction costs; it does not indicate recurring operating profitability. Excluding the gain, operating expenses were lower than in the comparable 2022 periods. No revenue-based margins are meaningful.
At June 30, 2023, cash and cash equivalents were $124.7 million; total assets were $133.8 million, total liabilities $11.8 million, and stockholders’ equity $122.0 million. The $15.0 million term loan, plus interest and other charges, was repaid in full and the facility terminated on June 9. Cash, cash equivalents and restricted cash increased $32.5 million during the first half, chiefly reflecting $83.7 million of asset-sale proceeds, offset by operating cash use and debt repayment.
Material changes versus prior comparable periods
Quarterly operating expenses declined $12.0 million year over year: R&D fell $7.7 million and G&A fell $4.3 million. For the first half, operating expenses declined $16.2 million year over year. Net income replaced prior-year losses in both periods because of the asset-sale gain; AVROBIO continued to use cash in operations.
Outlook, commentary and risks
AVROBIO received $87.5 million cash consideration from Novartis for its cystinosis gene therapy program and related assets, completed June 9. Management estimated June 30 cash would fund operating expenses and capital needs at least into the fourth quarter of 2024; the filing cautions that this estimate depends on assumptions. The company also described cash as sufficient for at least the next 12 months from the filing date.
The board approved halting program development and exploring alternatives including a sale, merger, business combination or divestiture. No definitive path or timetable was set; if no transaction is completed, the board may consider dissolution and liquidation. A workforce reduction of approximately 50% was substantially completed by late July. Estimated severance and termination costs were approximately $2.8 million, expected mainly in Q3 2023.
Key risks include uncertainty about a strategic transaction and any value returned to stockholders, cash consumption and additional strategic-review costs, contractual and contingent obligations, and possible liquidation. Product development is halted; any resumption would require substantial funding. The filing also notes Nasdaq minimum-bid-price compliance risk. Management reported disclosure controls were effective as of June 30, 2023 and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is AVROBIO, Inc., despite the request metadata naming Tectonic Therapeutic, Inc.
- Track strategic-review developments, transaction terms, timing, and any decision to liquidate; no outcome was assured.
- Assess cash use, remaining obligations, strategic-review expenses, and whether the stated cash runway remains achievable.
- Verify the treatment and timing of the estimated $2.8 million severance costs and other post-quarter expenses.
- Check the status of the halted programs, related licenses and commitments, and Nasdaq listing compliance.